Anti-transferrin receptor antibodies and methods of use
AssigneeGenentech, Inc.
InventorsYin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S. Dennis, James A. Ernst, Ryan J. Watts, Gregory A. Lazar
Life of this patent
Estimating the term…
Abstract
The present invention relates to anti-transferrin receptor antibodies and methods of their use.
Claims52
-63. (canceled)
A method of transporting a compound across the BBB in a subject comprising exposing an antibody coupled to the compound to the BBB such that the antibody transports the compound coupled thereto across the BBB, wherein the antibody binds to human transferrin receptor (TfR) and comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 53, HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 156, HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 55, HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 50, HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 51, and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 52.
A method of increasing exposure of the CNS of a subject to a compound, comprising exposing an antibody coupled to the compound to the BBB such that the antibody transports the compound coupled thereto across the BBB, wherein the antibody binds to human transferrin receptor (TfR) and comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 53, HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 156, HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 55, HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 50, HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 51, and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 52.
A method of increasing retention in the CNS of a compound administered to a subject, comprising exposing an antibody coupled to the compound to the BBB such that the retention in the CNS of the compound is increased, wherein the antibody binds to human transferrin receptor (TfR) and comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 53, HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 156, HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 55, HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 50, HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 51, and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 52.
A method of treating a neurological disorder in a mammal comprising treating the mammal with an antibody coupled to a therapeutic compound, wherein the antibody binds to human transferrin receptor (TfR) and comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 53, HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 156, HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 55, HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 50, HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 51, and HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 52.
Dependencies are inferred from the claim text.